Caricamento...
Cabozantinib for the treatment of kidney cancer
INTRODUCTION: Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recently approved by the Food and Drug Administration for the treatment of metastatic renal cell carcinoma after progression on first line therapy. AREAS COVERE...
Salvato in:
| Pubblicato in: | Expert Rev Anticancer Ther |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166873/ https://ncbi.nlm.nih.gov/pubmed/28633552 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14737140.2017.1344553 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|